Non-Selected Compounds. The rights granted to MRE under Section ---------------------- 2.1 shall revert to DTI with respect to the following compounds (hereinafter all such compounds shall be referred to as the "Non-Selected Compounds"): (i) those Licensed Compounds which MRE did not select for clinical development during the Discovery and Development Term and (ii) those Selected Compounds with respect to which MRE has not (a) initiated animal toxicology studies within two (2) years of being designated a "Selected Compound" and (b) filed an IND within three (3) years of such selection.
Appears in 2 contracts
Sources: Development and Commercialization Agreement (Aderis Pharmaceuticals Inc), Development and Commercialization Agreement (Aderis Pharmaceuticals Inc)
Non-Selected Compounds. The rights granted to MRE under Section ----------------------
2.1 shall revert to DTI with respect to the following compounds (hereinafter all such compounds shall be referred to as the "Non-Selected Compounds"):
(i) those Licensed Compounds which MRE did not select for clinical development during the Discovery and Development Term and (ii) those Selected Compounds with respect to which MRE has not (a) initiated animal toxicology studies within two (2) years of being designated a "Selected Compound" and (b) filed an IND within three (3) years of such selection.
Appears in 1 contract
Sources: Development and Commercialization Agreement (Aderis Pharmaceuticals Inc)